Abstract
A new, enantioselective synthesis of Orlistat suitable for large-scale production is described, wherein the first enantiomerically pure intermediate methyl (R)-3-hydroxy-tetradecanoate is prepared via asymmetric hydrogenation of methyl 3-oxotetradecanoate. The relevant criteria associated with the application of the asymmetric hydrogenation technology are addressed, such as the activity, the selectivity and the availability of the catalyst as well as the quality of the hydrogenation substrate and the hydrogen gas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
